The French EsoGastricTumours Data Base — FREGAT

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Esophageal Disease Clinical Trial

Official title:
National Oesophageal and Gastric Carcinomas Data Base Construction: the FREGAT (French EsoGastric Tumours) Data Base

Status Recruiting

Clinical Trial Summary

This retrospective study aims at evaluating the outcomes of gastrointestinal stromal tumor after surgery.

n/a

NCT number	NCT02526095
Study type	Observational [Patient Registry]
Source	University Hospital, Lille
Contact	Guillaume Piessen, MD, PhD
Phone	+3320444407
Email	guillaume.piessen@chru-lille.fr
Status	Recruiting
Phase
Start date	June 2014
Completion date	May 2027

See also
Status	Clinical Trial	Phase
Completed	`NCT02105506` - Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses	N/A
Completed	`NCT01360515` - A Study of Disposable Transnasal Esophagoscope	N/A
Completed	`NCT04001400` - Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.	Phase 3
Completed	`NCT03998969` - Efficacy of DA-5204 on Gastroesophageal Reflux Disease	Phase 3
Completed	`NCT01927016` - Outcomes After Esophageal Cancer Surgery	N/A